sitravatinib + rifampin

**Sitravatinib + rifampin** is a combination of two drugs: sitravatinib, a small molecule oral multi-kinase inhibitor with antineoplastic (anticancer) activity, and rifampin, an antibiotic of the rifamycin class known for its use in tuberculosis and as a potent inducer of several cytochrome P450 enzymes, including CYP3A4. Sitravatinib targets multiple receptor tyrosine kinases (RTKs) implicated in tumor growth and the immunosuppressive tumor microenvironment, specifically inhibiting VEGFR, TAM family receptors (TYRO3, AXL, MERTK), MET, KIT, DDR2, PDGFR, RET, TRK, and Eph family kinases. Rifampin is not used as an oncologic therapy but is relevant pharmacologically for its strong induction of CYP3A4, which can significantly reduce plasma levels of other drugs metabolized by this enzyme, including sitravatinib. The combination is not an approved therapy; it may be studied in drug-drug interaction research or for pharmacokinetic modulation. There are no clinical trials or clinical uses specifically for this combination as therapy; rather, the relevance of this combination is as an example of a clinically significant drug-drug interaction, where rifampin can decrease efficacy of sitravatinib by increasing its metabolism[3].